

# FY4/22 2Q Supplementary Materials

## AIN HOLDINGS INC.

December 3, 2021

### 1. Consolidated Results

■Year-on-Year (¥ million)

|  | FY4/21 2Q<br>results  | FY4/22 2Q<br>results  | YoY<br>change | YoY<br>change(%) |
|--|-----------------------|-----------------------|---------------|------------------|
| Net sales  | 145,352               | 152,972               | +7,620        | +5.2             |
| Gross profit % of net sales                            | 21,435<br><b>14.7</b> | 22,838<br><b>14.9</b> | +1,403        | +6.5             |
| SG&A expenses % of net sales                           | 17,508<br><b>12.0</b> | 17,062<br><b>11.2</b> | (446)         | (2.5)            |
| Operating profit % of net sales                        | 3,927<br><b>2.7</b>   | 5,776<br><b>3.8</b>   | +1,849        | +47.1            |
| Ordinary profit % of net sales                         | 4,517<br><b>3.1</b>   | 6,127<br><b>4.0</b>   | +1,610        | +35.6            |
| Profit attributable to owners of parent % of net sales | 2,630<br>1.8          | 3,338<br>2.2          | +708          | +26.9            |
| Earnings per share(¥)                                  | 74.24                 | 94.68                 | +20.44        | +27.5            |

Figures in the table are rounded down

■Vs Plan (¥ million)

|  | FY4/22 2Q<br>plan     | FY4/22 2Q<br>results  | Vs plan<br>change | Vs plan<br>change(%) |
|--|-----------------------|-----------------------|-------------------|----------------------|
| Net sales  | 147,900               | 152,972               | +5,072            | +3.4                 |
| Gross profit % of net sales                            | 23,000<br><b>15.6</b> | 22,838<br><b>14.9</b> | (162)             | (0.7)                |
| SG&A expenses % of net sales                           | 17,700<br><b>12.0</b> | 17,062<br><b>11.2</b> | (638)             | (3.6)                |
| Operating profit % of net sales                        | 5,300<br><b>3.6</b>   | 5,776<br><b>3.8</b>   | +476              | +9.0                 |
| Ordinary profit<br>% of net sales                      | 5,600<br><b>3.8</b>   | 6,127<br><b>4.0</b>   | +527              | +9.4                 |
| Profit attributable to owners of parent % of net sales | 2,780<br><b>1.9</b>   | 3,338<br>2.2          | +558              | +20.1                |
| Earnings per<br>share(¥)                               | 78.47                 | 94.68                 | +16.21            | +20.7                |

Figures in the table are rounded down

## 2. Segment Information (Dispensing Pharmacy Business)

■Year-on-Year (¥ million)

|                                 | FY4/21 2Q<br>results  | FY4/22 2Q<br>results  | YoY<br>change | YoY<br>change(%) |
|---------------------------------|-----------------------|-----------------------|---------------|------------------|
| Net sales                       | 128,029               | 136,905               | +8,876        | +6.9             |
| Gross profit % of net sales     | 15,008<br><b>11.7</b> | 17,115<br><b>12.5</b> | +2,107        | +14.0            |
| SG&A expenses % of net sales    | 7,109<br><b>5.6</b>   | 6,902<br><b>5.0</b>   | (207)         | (2.9)            |
| Operating profit % of net sales | 7,898<br><b>6.2</b>   | 10,212<br><b>7.5</b>  | +2,314        | +29.3            |
| Segment profit % of net sales   | 8,370<br><b>6.5</b>   | 10,491<br><b>7.7</b>  | +2,121        | +25.3            |

Figures in the table are rounded down

■Vs Plan (¥ million)

|                                 | FY4/22 2Q<br>plan     | FY4/22 2Q<br>results  | Vs plan<br>change | Vs plan<br>change(%) |
|---------------------------------|-----------------------|-----------------------|-------------------|----------------------|
| Net sales                       | 130,400               | 136,905               | +6,505            | +5.0                 |
| Gross profit % of net sales     | 16,300<br><b>12.5</b> | 17,115<br><b>12.5</b> | +815              | +5.0                 |
| SG&A expenses<br>% of net sales | 7,200<br><b>5.5</b>   | 6,902<br><b>5.0</b>   | (298)             | (4.1)                |
| Operating profit % of net sales | 9,100<br><b>7.0</b>   | 10,212<br><b>7.5</b>  | +1,112            | +12.2                |
| Segment profit % of net sales   | 9,300<br><b>7.1</b>   | 10,491<br><b>7.7</b>  | +1,191            | +12.8                |

Figures in the table are rounded down

Segment profit is adjusted to ordinary income shown on the quarterly consolidated statements of income

Segment profit is adjusted to ordinary income shown on the quarterly consolidated statements of income

## 3. Segment Information (Cosmetic and Drug Store Business)

■Year-on-Year (¥ million)

|                                 | FY4/21 2Q<br>results | FY4/22 2Q<br>results | YoY<br>change | YoY<br>change(%) |
|---------------------------------|----------------------|----------------------|---------------|------------------|
| Net sales                       | 9,388                | 9,816                | +428          | +4.6             |
| Gross profit % of net sales     | 3,469<br><b>37.0</b> | 3,321<br><b>33.8</b> | (148)         | (4.3)            |
| SG&A expenses<br>% of net sales | 4,596<br><b>49.0</b> | 4,475<br><b>45.6</b> | (121)         | (2.6)            |
| Operating profit % of net sales | (1,127)<br>-         | (1,153)<br>-         | (26)          | -                |
| Segment profit % of net sales   | (1,014)              | (1,125)<br>-         | (111)         | -                |

Figures in the table are rounded down

■Vs Plan (¥ million)

|                                 | FY4/22 2Q<br>plan    | FY4/22 2Q<br>results | Vs plan<br>change | Vs plan<br>change(%) |
|---------------------------------|----------------------|----------------------|-------------------|----------------------|
| Net sales                       | 10,630               | 9,816                | (814)             | (7.7)                |
| Gross profit % of net sales     | 3,890<br><b>36.6</b> | 3,321<br><b>33.8</b> | (569)             | (14.6)               |
| SG&A expenses % of net sales    | 4,840<br><b>45.5</b> | 4,475<br><b>45.6</b> | (365)             | (7.5)                |
| Operating profit % of net sales | (950)<br>-           | (1,153)<br>-         | (203)             | -                    |
| Segment profit % of net sales   | (930)<br>-           | (1,125)<br>-         | (195)             | -                    |

Figures in the table are rounded down

Segment profit is adjusted to ordinary income shown on the quarterly consolidated statements of income

Segment profit is adjusted to ordinary income shown on the quarterly consolidated statements of income

## 4. Sales Verification

| ■ Dispensing Ph                          | armacy B  | Business (Y            | <b>'oY)</b> (%)                  | ■ Dispensing Ph                          | narmacy B | usiness (\             | <b>/s Plan)</b> (%)              |
|--|-----------|------------------------|----------------------------------|--|-----------|------------------------|----------------------------------|
|  | Net sales | Prescription<br>volume | Average<br>prescription<br>price |  | Net sales | Prescription<br>volume | Average<br>prescription<br>price |
| Same store (1,029)                       | +3.2      | +3.2                   | 0.0                              | Same store (1,029)                       | +6.1      | +1.6                   | +4.5                             |
| Store openings in the previous year (29) | +398.6    | +560.8                 | (24.6)                           | Store openings in the previous year (29) | (5.3)     | (6.7)                  | +1.5                             |
| Total (1,091)                            | +6.8      | +5.7                   | +1.1                             | Total (1,091)                            | +4.9      | +0.2                   | +4.7                             |

| ■ Cosmetic and Drug Store Business (YoY) (%) ■ Cosmetic and Drug Store Business (Vs Plan) (%) |           |                     |                                     |  |           |                     |                                     |  |  |
|---|-----------|---------------------|-------------------------------------|--|-----------|---------------------|-------------------------------------|--|--|
|   | Net sales | Number of customers | Average<br>spending per<br>customer |  | Net sales | Number of customers | Average<br>spending per<br>customer |  |  |
| Same store (56)   | +3.9      | +4.4                | (0.5)                               | Same store (56)                          | (4.5)     | (5.1)               | +0.7                                |  |  |
| Store openings in the previous year (11)  | +340.2    | +411.4              | (13.9)                              | Store openings in the previous year (11) | (16.0)    | (11.5)              | (5.0)                               |  |  |
| Total (72)  | +11.2     | +12.6               | (1.2)                               | Total (72)                               | (7.7)     | (7.0)               | (0.7)                               |  |  |

Changed accounting policies for revenue recognition from FY4/22

#### (Reference)

| ■ Cosmetic and Drug Store Business (YoY) (%) |           |                     |                                     | ■ Cosmetic and D                         | rug Store | Business (\         | <b>/s Plan)</b> (%)           |
|--|-----------|---------------------|-------------------------------------|--|-----------|---------------------|-------------------------------|
|  | Net sales | Number of customers | Average<br>spending per<br>customer |  | Net sales | Number of customers | Average spending per customer |
| Same store (56)                              | +3.2      | 4.4                 | (1.1)                               | Same store (56)                          | (3.3)     | (5.1)               | +2.0                          |
| Store openings in the previous year (11)     | +383.8    | 411.4               | (5.4)                               | Store openings in the previous year (11) | (13.8)    | (11.5)              | (2.6)                         |
| Total (72)                                   | +10.6     | 12.6                | (1.8)                               | Total (72)                               | (6.3)     | (7.0)               | +0.7                          |

For comparison purposes, FY4/22 figures are calculated to adjust to the results before the changes in accounting policies for revenue recognition

#### 5. Consolidated Balance Sheet

■ Assets (¥ million)

|                                    | End-FY4/21 2Q | End-FY4/21 | End-FY4/22 2Q | Change  |
|------------------------------------|---------------|------------|---------------|---------|
| Cash on hand and in banks          | 54,616        | 55,271     | 58,692        | +3,421  |
| Notes and accounts receivable      | 11,953        | 13,475     | 9,928         | (3,547) |
| Inventories                        | 14,796        | 14,285     | 16,312        | +2,027  |
| Total current assets               | 94,006        | 96,398     | 98,561        | +2,163  |
| Buildings and structures,net       | 16,225        | 16,270     | 17,034        | +764    |
| Land                               | 10,409        | 10,390     | 10,030        | (360)   |
| Lease assets                       | 166           | 100        | 58            | (42)    |
| Total property,plant and equipment | 30,169        | 30,229     | 31,266        | +1,037  |
| Goodwill                           | 40,563        | 39,057     | 39,133        | +76     |
| Lease assets                       | 3             | 1          | 0             | (1)     |
| Total intangible fixed assets      | 43,715        | 42,666     | 43,180        | +514    |
| Investments in securities          | 2,335         | 2,697      | 2,429         | (268)   |
| Deferred tax assets                | 4,315         | 4,415      | 4,629         | +214    |
| Deposits and guarantees            | 19,493        | 20,319     | 22,951        | +2,632  |
| Total investments and other assets | 31,629        | 34,368     | 37,434        | +3,066  |
| Total fixed assets                 | 105,514       | 107,264    | 111,881       | +4,617  |
| Total deferred assets              | -             | -          | -             | -       |
| Total assets                       | 199,521       | 203,662    | 210,442       | +6,780  |

Figures in the table are rounded down

Change:End-FY4/22 2Q compared with end-FY4/21

#### ■ Liabilities and Net Assets

(¥ million)

|                                       | End-FY4/21 2Q | End-FY4/21              | End-FY4/22 2Q | Change  |
|---------------------------------------|---------------|-------------------------|---------------|---------|
| Accounts payable                      | 45,619        | 46,758                  | 51,465        | +4,707  |
| Short-term debt                       | 4,694         | 3,670                   | 3,051         | (619)   |
| Lease obligations                     | 137           | 94                      | 57            | (37)    |
| Total current liabilities             | 73,275        | 74,160                  | 81,959        | +7,799  |
| Long-term debt                        | 9,165         | 8,297                   | 6,860         | (1,437) |
| Lease obligations                     | 82            | 37                      | 17            | (20)    |
| Total long-term liabilities           | 14,526        | 13,664                  | 12,672        | (992)   |
| Total liabilities                     | 87,802        | 87,825                  | 94,632        | +6,807  |
| Common stock                          | 21,894        | 21,894                  | 21,894        | -       |
| Capital surplus                       | 20,500        | 20,500                  | 20,500        | -       |
| Retained earnings                     | 69,439        | 73,506                  | 74,907        | +1,401  |
| Total shareholders' equity            | 111,832       | 115,899                 | 115,899       | -       |
| Total net assets                      | 111,719       | 115,837                 | 115,810       | (27)    |
| Total liabilities and net assets      | 199,521       | 203,662                 | 210,442       | +6,780  |
| Figures in the table are rounded down | Change:End-FY | 4/22 2Q compared with 6 | end-FY4/21    |         |

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥6,630million

## 6. FY4/22 Plan (Consolidated)

(¥ million)

|  | (                     |                       |                       |               |                   |  |  |
|--|-----------------------|-----------------------|-----------------------|---------------|-------------------|--|--|
|  | FY4/20<br>results     | FY4/21<br>results     | FY4/22<br>plan        | YoY<br>change | YoY<br>change (%) |  |  |
| Net sales  | 292,615               | 297,305               | 315,000               | +17,695       | +6.0              |  |  |
| Gross profit % of net sales                            | 46,861<br><b>16.0</b> | 46,155<br><b>15.5</b> | 51,600<br><b>16.4</b> | +5,445        | +11.8             |  |  |
| SG&A expenses % of net sales                           | 30,793<br><b>10.5</b> | 35,222<br>11.8        | 36,600<br>11.6        | +1,378        | +3.9              |  |  |
| Operating profit % of net sales                        | 16,068<br><b>5.5</b>  | 10,932<br><b>3.7</b>  | 15,000<br>4.8         | +4,068        | +37.2             |  |  |
| Ordinary profit % of net sales                         | 16,822<br><b>5.7</b>  | 12,649<br><b>4.3</b>  | 15,500<br><b>4.9</b>  | +2,851        | +22.5             |  |  |
| Profit attributable to owners of parent % of net sales | 9,179<br><b>3.1</b>   | 6,697<br><b>2.3</b>   | 8,300<br><b>2.6</b>   | +1,603        | +23.9             |  |  |
| Earnings per share(¥)                                  | 259.11                | 189.04                | 234.28                | +45.24        | +23.9             |  |  |
| Annual dividend (¥)                                    | 55.00                 | 55.00                 | 55.00                 | 0.0           | 0.0               |  |  |

Figures in the table are rounded down

<sup>▶</sup> Change:FY4/22 plan compared with FY4/21 results

#### 7. Transition of Store Openings

#### ■ Number of Store Openings in Dispensing Pharmacy Business

|         | FY4/14 | FY4/15 | FY4/16 | FY4/17 | FY4/18 | FY4/19 | FY4/20 | FY4/21 | FY4/22<br>2Q |
|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------------|
| Organic | 36     | 40     | 32     | 27     | 25     | 23     | 14     | 15     | 12           |
| M&A     | 26     | 119    | 110    | 182    | 11     | 134    | 6      | 14     | 21           |
| Total   | 616    | 754    | 881    | 1,066  | 1,029  | 1,132  | 1,088  | 1,065  | 1,091        |

#### ■ Number of Store Openings in Cosmetic and Drug Store Business

|         | FY4/14 | FY4/15 | FY4/16 | FY4/17 | FY4/18 | FY4/19 | FY4/20 | FY4/21 | FY4/22<br>2Q |
|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------------|
| Organic | 3      | 3      | 5      | 9      | 4      | 7      | 15     | 11     | 4            |
| Total   | 59     | 56     | 52     | 52     | 48     | 54     | 63     | 69     | 72           |

### Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

